Vaccines and Therapeutics

Effective delivery into target cells is the major obstacle in the development of oligonucleotide based vaccines and therapeutics. 20Med Nanoparticle delivery technology can provide solutions for effective delivery in a wide range of therapeutic areas.

Prophylactic Vaccines

RNA and DNA-based vaccines provide an attractive alternative to conventional vaccine development, allowing for rapid development of a highly potent, low-cost approach. A major hurdle has been the instability of mRNA and the low efficiency of in-vivo delivery. 20Med Nanoparticles overcome this problem by protecting the mRNA payload during administration and cell entry followed by rapid release of the payload in the cytosol. 20Med is applying its unique delivery platform for the development of prophylactic vaccines against infectious diseases for applications in human and animal health.

Tumor Specific Cancer Vaccines

Recent advancements in cancer characterization and tumor sequencing have made it possible to identify tumor-specific neoantigens for the development of personalized cancer immuno-therapeutics. Based on the same vaccine delivery platform, 20Med Nanoparticles can be used for the development of mRNA based neoantigen cancer vaccines. The ready-to-use particles can easily be combined with neoantigen-mRNA in a one-step loading and formulation process making the technology suitable for rapid development of patient-specific cancer vaccines.

In-vivo CAR-T Applications

To further explore the potential of its Nanoparticle delivery technology in immuno-oncology applications, 20Med Therapeutics has founded a joint-venture, NanoCell Therapeutics Inc. Based in Philadelphia, NanoCell is focused on the development of ex-vivo and in-vivo Car T-cell applications. For more information please visit Nanocelltx.com

mRNA Therapeutics

mRNA based therapeutics are a highly attractive new class of biologics with the potential to encode for any protein of interest directly in-vivo. The promise of mRNA therapeutics as the replacement of protein therapeutics has been hampered by the relative instability of mRNA and ineffective delivery into the cell. 20Med's Nanoparticle delivery technology protects mRNA against degradation during administration and circulation, followed by efficient cell entry and release of the payload in the cytosol. By providing an efficient, low-cost carrier for mRNA therapeutics the 20Med Nanoparticle technology has the potential to transform the mRNA therapeutics market.

  • Partnering Inquiries

    Please contact us at BD@20medtx.com for any partnership inquiries or business opportunities.